BioLineRx Interest Income vs Gross Profit Analysis
BLRX Stock | USD 0.32 0.23 41.82% |
BioLineRx financial indicator trend analysis is way more than just evaluating BioLineRx prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioLineRx is a good investment. Please check the relationship between BioLineRx Interest Income and its Gross Profit accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.
Interest Income vs Gross Profit
Interest Income vs Gross Profit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioLineRx Interest Income account and Gross Profit. At this time, the significance of the direction appears to have weak relationship.
The correlation between BioLineRx's Interest Income and Gross Profit is 0.38. Overlapping area represents the amount of variation of Interest Income that can explain the historical movement of Gross Profit in the same time period over historical financial statements of BioLineRx, assuming nothing else is changed. The correlation between historical values of BioLineRx's Interest Income and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Income of BioLineRx are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Interest Income i.e., BioLineRx's Interest Income and Gross Profit go up and down completely randomly.
Correlation Coefficient | 0.38 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Gross Profit
Gross profit is a required income statement account that reflects total revenue of BioLineRx minus its cost of goods sold. It is profit before BioLineRx operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most indicators from BioLineRx's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioLineRx current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.At this time, BioLineRx's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 22.8 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (2.78) in 2024.
BioLineRx fundamental ratios Correlations
Click cells to compare fundamentals
BioLineRx Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioLineRx fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 53.6M | 47.3M | 81.4M | 76.4M | 63.9M | 53.7M | |
Other Current Liab | 7K | 1.4M | 1.2M | 1.3M | 3.4M | 3.5M | |
Total Current Liabilities | 12.0M | 10.6M | 9.7M | 10.7M | 30.9M | 32.4M | |
Total Stockholder Equity | 33.4M | 22.0M | 68.1M | 50.8M | 13.2M | 12.6M | |
Other Liab | 323K | 658K | 10.2M | 1.9M | 2.1M | 2.2M | |
Accounts Payable | 7.8M | 5.9M | 5.6M | 7.0M | 10.9M | 11.4M | |
Cash | 5.3M | 16.8M | 13.0M | 10.6M | 4.3M | 8.0M | |
Long Term Debt | 7.8M | 5.8M | 2.7M | 8.6M | 6.6M | 3.6M | |
Common Stock Shares Outstanding | 9.8M | 16.9M | 44.2M | 51.6M | 64.2M | 67.4M | |
Short Term Investments | 22.2M | 5.8M | 44.1M | 40.5M | 38.7M | 28.6M | |
Other Current Assets | 108K | 152K | 127K | 198K | 1.5M | 1.5M | |
Total Liab | 20.2M | 25.3M | 13.3M | 25.5M | 50.7M | 53.2M | |
Intangible Assets | 21.9M | 21.7M | 21.7M | 21.9M | 14.9M | 10.4M | |
Common Stock | 4.7M | 9.9M | 21.1M | 27.1M | 31.4M | 32.9M | |
Property Plant Equipment | 2.2M | 3.5M | 2.7M | 2.3M | 2.6M | 2.1M | |
Short Long Term Debt Total | 10.5M | 7.7M | 4.7M | 12.3M | 11.6M | 12.2M | |
Property Plant And Equipment Net | 3.5M | 2.7M | 2.3M | 2.5M | 1.9M | 2.2M | |
Net Debt | 5.2M | (9.1M) | (8.3M) | 1.7M | 7.3M | 7.7M | |
Retained Earnings | (248.0M) | (278.0M) | (305.0M) | (330.0M) | (390.6M) | (371.1M) | |
Non Current Assets Total | 25.4M | 24.4M | 24.0M | 24.4M | 16.7M | 13.7M | |
Non Currrent Assets Other | 56K | 25.4M | 21.4M | (1.0) | (1.15) | (1.09) | |
Cash And Short Term Investments | 27.5M | 22.6M | 57.1M | 51.1M | 43.0M | 39.3M | |
Net Receivables | 613K | 141K | 142K | 721K | 708K | 430.0K | |
Common Stock Total Equity | 2.8M | 3.1M | 4.7M | 9.9M | 11.4M | 11.9M | |
Liabilities And Stockholders Equity | 53.6M | 47.3M | 81.4M | 76.4M | 63.9M | 54.1M | |
Non Current Liabilities Total | 8.2M | 14.6M | 3.6M | 14.9M | 19.8M | 20.8M | |
Other Stockholder Equity | 265.9M | 279.2M | 339.3M | 339.0M | 355.5M | 255.4M | |
Property Plant And Equipment Gross | 3.5M | 2.7M | 6.8M | 2.5M | 7.4M | 7.8M | |
Total Current Assets | 28.2M | 22.9M | 57.4M | 52.0M | 47.2M | 40.4M | |
Accumulated Other Comprehensive Income | 10.7M | 10.9M | 11.7M | 13.3M | 17.0M | 10.8M | |
Short Term Debt | 2.9M | 3.3M | 2.9M | 2.4M | 3.7M | 3.9M | |
Net Tangible Assets | 19.3M | 11.5M | 316K | 46.4M | 41.7M | 22.1M | |
Short Long Term Debt | 2.7M | 3.1M | 2.8M | 1.5M | 3.1M | 1.8M | |
Net Invested Capital | 41.9M | 27.9M | 70.8M | 61.0M | 23.0M | 37.5M | |
Net Working Capital | 16.2M | 12.2M | 47.7M | 41.3M | 16.3M | 23.2M | |
Capital Stock | 4.7M | 9.9M | 21.1M | 27.1M | 31.4M | 17.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.